Regeneron drops eye-drug combination as Novartis chases Eylea


REUTERS: Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine. Results from two mid-stage clinical trials that added nesvacumab to Eylea "did not provide sufficient differentiation to warrant Phase 3 development", Regeneron said on Monday.



from Biotech News